Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
67.8M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
22.9M
-
Shares change
-
-1.26M
-
Total reported value, excl. options
-
$68.9M
-
Value change
-
-$4.06M
-
Number of buys
-
16
-
Number of sells
-
-21
-
Price
-
$3.01
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) as of Q3 2019
45 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2019.
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.9M shares
of 67.8M outstanding shares and own 33.78% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.77M shares), ADAMS STREET PARTNERS LLC (3.28M shares), BVF INC/IL (3.05M shares), Novo Holdings A/S (2.93M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.6M shares), MILLENNIUM MANAGEMENT LLC (952K shares), RENAISSANCE TECHNOLOGIES LLC (852K shares), VANGUARD GROUP INC (574K shares), DIMENSIONAL FUND ADVISORS LP (475K shares), and FMR LLC (427K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.